Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Atea Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 127 | 1 | 124 | −2 |
| Shares | 60.1M | 1.03K | 59.4M | −660.9K (−1.1%) |
| Value | $322.8M | $5.53K | $276.4M | −$46.4M (−14.4%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Algert Global LLC | 38,520 | $179.1K | 0.00% |
| Mercer Global Advisors Inc | 27,860 | $129.5K | 0.00% |
| Engineers Gate Manager LP | 16,806 | $78.1K | 0.00% |
| Headlands Technologies LLC | 16,619 | $77.3K | 0.01% |
| Cerity Partners LLC | 16,471 | $76.6K | 0.00% |
| Spark Investment Management LLC | 16,200 | $75.3K | 0.15% |
| Graham Capital Management, L.P. | 16,145 | $75.1K | 0.00% |
| Bailard, Inc. | 16,100 | $74.9K | 0.00% |
| Trexquant Investment LP | 14,751 | $68.6K | 0.00% |
| Neuberger Berman Group LLC | 12,077 | $56.2K | 0.00% |
| SRS Capital Advisors, Inc. | 4,224 | $19.6K | 0.00% |
| Versant Capital Management, Inc | 4,220 | $19.6K | 0.00% |
| SJS Investment Consulting Inc. | 256 | $1.19K | 0.00% |
| Zions Bancorporation, National Association | 128 | $595 | 0.00% |
| Global Retirement Partners, LLC | 123 | $572 | 0.00% |
| True Wealth Design, LLC | 122 | $568 | 0.00% |
| Clearstead Advisors, LLC | 22 | $103 | 0.00% |
| Covestor Ltd | 36 | $0 | 0.00% |
Sold out (20)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Jane Street Group, LLC | 418,296 | $2.25M |
| Irenic Capital Management LP | 301,699 | $1.62M |
| Peapod Lane Capital LLC | 272,820 | $1.44M |
| Point72 Asset Management, L.P. | 119,553 | $643.2K |
| EAM Investors, LLC | 112,866 | $607.2K |
| Alps Advisors Inc | 64,862 | $349.0K |
| Empowered Funds, LLC | 49,469 | $266.1K |
| Jacobs Levy Equity Management, Inc | 43,104 | $231.9K |
| Virtu Financial LLC | 34,030 | $183.0K |
| XTX Topco Ltd | 23,141 | $124.5K |
| Axq Capital, LP | 18,181 | $97.8K |
| Connor, Clark & Lunn Investment Management Ltd. | 12,985 | $69.9K |
| Two Sigma Securities, LLC | 12,131 | $65.3K |
| JustInvest LLC | 11,464 | $61.7K |
| Optiver Holding B.V. | 670 | $3.60K |
| Jones Financial Companies LLLP | 207 | $1.06K |
| Federated Hermes, Inc. | 143 | $769 |
| MAI Capital Management | 132 | $711 |
| Root Financial Partners, LLC | 84 | $452 |
| US Bancorp | 64 | $344 |
Not filed for Q2 2026 yet (1)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 1,027 | $5.53K |